9342-8530 Quebec Inc DGCRF

Due Bill Period

[Dibah42]

So what do you think we'll be trading at once this "doobill-schmoobill" is out of the way next week?
And which market will CUR be traded on?  Here's a list of assets:  1) PCP  2)GCC  3) biospecimens  4) tax losses  5) misc.
PCP:  For their star performer PCA3, which was approved by FDA, CE Mark, Health Canada etc and had a healthy record of multi-year sales, management managed to get $6.5m.  To my knowledge PCP has yet to obtain any approvals.
GCC:  Sale to Signal Genetics was so long ago I've forgotten the price. Much of the value was in the Philly Lab.  And when management bought back the rights they paid a few hundred thousand dollars if my memory is correct.
Biospecimens:  Don't know how to assess peeandtissue samples etc so won't go there.  Suppose there is some value there for other research labs.
Tax Losses:  Have no idea how value is realized here. In the "golden" days, i.e. the good old days of the energy boom oil & gas companies would buy up tax losses by the bushel.  Nowadays they are themselves tax losses and are being gobbled up by the bigger fish.

And yes there seems to be buying interest in CUR above $0.12  these past few days  so obviously buyers believe their is value beyond the ROC.

What do you think?